These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37773189)

  • 1. Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start.
    Ciurea A; Distler O; Kwok K; Jo H; Wang L; Killeen T; Ospelt C; Frank Bertoncelj M
    Arthritis Res Ther; 2023 Sep; 25(1):185. PubMed ID: 37773189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofacitinib versus methotrexate in rheumatoid arthritis.
    Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
    N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
    Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
    Takeuchi T; Fleischmann R; Iikuni N; Shi H; Soma K; Paulissen J; Hirose T; Smolen JS
    Arthritis Res Ther; 2021 Aug; 23(1):220. PubMed ID: 34429160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
    Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
    Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
    Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B
    Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
    van der Heijde D; Strand V; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
    Arthritis Rheumatol; 2019 Jun; 71(6):878-891. PubMed ID: 30666826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
    van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; García Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B;
    N Engl J Med; 2012 Aug; 367(6):508-19. PubMed ID: 22873531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.
    Strand V; Lee EB; Yazici Y; Dikranian A; Wilkinson B; Takiya L; Zang C; Bananis E; Bergman MJ
    Clin Rheumatol; 2018 Aug; 37(8):2043-2053. PubMed ID: 29656373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
    Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
    van der Heijde D; Tanaka Y; Fleischmann R; Keystone E; Kremer J; Zerbini C; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Wyman BT; Gruben D; Benda B; Wallenstein G; Krishnaswami S; Zwillich SH; Bradley JD; Connell CA;
    Arthritis Rheum; 2013 Mar; 65(3):559-70. PubMed ID: 23348607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis.
    Conaghan PG; Østergaard M; Troum O; Bowes MA; Guillard G; Wilkinson B; Xie Z; Andrews J; Stein A; Chapman D; Koenig A
    Arthritis Res Ther; 2019 Oct; 21(1):214. PubMed ID: 31639034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
    Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
    Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses.
    Strand V; Kavanaugh A; Kivitz AJ; van der Heijde D; Kwok K; Akylbekova E; Soonasra A; Snyder M; Connell C; Bananis E; Smolen JS
    Rheumatol Ther; 2018 Dec; 5(2):341-353. PubMed ID: 29761420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
    Mueller RB; Schulze-Koops H; Furst DE; Cohen SB; Kwok K; Wang L; Killeen T; von Kempis J
    Clin Rheumatol; 2022 Apr; 41(4):1045-1055. PubMed ID: 34973077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
    Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
    Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis.
    Bergman M; Tundia N; Yang M; Orvis E; Clewell J; Bensimon A
    Adv Ther; 2021 Dec; 38(12):5649-5661. PubMed ID: 34636000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies.
    van der Heijde D; Landewé RBM; Wollenhaupt J; Strengholt S; Terry K; Kwok K; Wang L; Cohen S
    Rheumatology (Oxford); 2021 Apr; 60(4):1708-1716. PubMed ID: 33057725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.